Futura Medical
Guildford, United Kingdom

Futura Medical is a R&D-driven small pharma with a novel proprietary transdermal delivery system, DermaSys, and a lead programme, MED3000, in development for erectile dysfunction.


Investment Perspective

Futura Medical is approaching a key point as the first of the regulatory filings for its novel erectile dysfunction (ED) treatment, MED3000, is expected within the next few months. MED3000 is a fast-acting gel that has proven clinical efficacy, a fast onset of action, and an attractive commercial profile. The ED market opportunity is sizeable, especially once MED3000 becomes widely available over the counter (OTC). Optimally addressing the various elements of the demographic segments and needs of the different geographies will, in our view, require careful selection of commercial partners. We expect the partnering discussions to start in earnest once the status of the regulatory approvals is known. Our DCF-based model, using conservative assumptions, values Futura Medical at £153.8m, equivalent to 60.9p a share.

Market information

SymbolPrimary exchanges


MED3000 on course for OTC approval in Europe and US
Update | 16 Sep 2020
FDA green lights MED3000 for OTC approval
Update | 14 Jul 2020
AGM statement confirms MED3000 filings on track
Update | 29 Jun 2020

Recent News

H120 interim results
16 Sep 2020
Positive QMS audit opinion received
10 Aug 2020
Update on CBD100 first stage development work
04 Aug 2020
EU and US regulatory update
14 Jul 2020